Gönül Veliçelebi

TorreyPines Therapeutics, formerly Neurogenetics, Inc., was founded in 2000. The company discovers & develops small molecule drugs to treat diseases and disorders of the central nervous system. The company is located in La Jolla, CA

CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA.

TorreyPines Therapeutics, Inc. manufactures and distributes biopharmaceutical products. The company develops small molecule drugs to treat diseases and disorders of the central nervous system, chronic pain, neuropathic pain, cognitive disorders and alzheimer's disease. It was formerly known as Axonyx, Inc. The company is headquartered in La Jolla, CA.

MitoKor, Inc. provided discovery and diagnostic development of mitochondrial medicine. It was a biotechnology company focused on the research and development of drugs for the treatment of major diseases and conditions associated with mitochondrial dysfunction. The company was headquartered in San Diego, CA

Orphagen Pharmaceuticals develops and manufactures drugs. The company was founded by Scott Thacher in 2001 and is headquartered in San Diego, CA.

Camino Pharma LLC is a start-up company based in the United States that focuses on discovering and developing first-in-class therapies for cancer and CNS disorders. The American company targets signaling proteins based on emerging biological concepts and discovers novel mechanisms for modulating these targets with small molecule drugs. Camino Pharma's leadership team has proven expertise in relevant target biology and extensive experience in drug discovery and development. The private company's goal is to discover and develop novel, first-in-class treatments for the most aggressive forms of cancer and poorly addressed psychiatric disorders, including substance use and major depression. Camino Pharma's innovative technology platform allows for exploiting inadequately served targets that require a highly adaptive and specialized approach to drug discovery.